Hermann Russ

Sentimetrix (United States) — United States

Neuroscience · Life Sciences

23h-index1.8kcitations66works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(19), Parkinson's Disease Mechanisms and Treatments(19), Neurological disorders and treatments(16), Receptor Mechanisms and Signaling(7), Neurotransmitter Receptor Influence on Behavior(6)

Publications66 total

Author Correction: The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
Scientific Reports·2025Open Access
GAL-201 as a Promising Amyloid-β-Targeting Small-Molecule Approach for Alzheimer’s Disease Treatment: Consistent Effects on Synaptic Plasticity, Behavior and Neuroinflammation
International Journal of Molecular Sciences·2025Open Access
GAL-101 prevents amyloid beta-induced membrane depolarization in two different types of retinal cells
2025Open Access
The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe
Scientific Reports·2023· 8 citedOpen Access
Amyotrophic Lateral Sclerosis Patients’ Preferences on Riluzole Treatment in Europe
Research Square (Research Square)·2023Open Access
The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer’s Disease
International Journal of Molecular Sciences·2022· 3 citedOpen Access
Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration
Investigative Ophthalmology & Visual Science·2021Open Access
Visual Field Endpoints Based on Subgroups of Points May Be Useful in Glaucoma Clinical Trials: A Study With the Humphrey Field Analyzer and Compass Perimeter
Journal of Glaucoma·2021· 3 citedOpen Access
Improved sensitivity of microperimetric outcomes for clinical studies in age-related macular degeneration
Scientific Reports·2021· 5 citedOpen Access
Sustained neuroprotective effect of novel Aβ aggregation modulator GAL-101 shown in dry AMD and glaucoma models with transient peak concentrations using eye drops
2019· 3 cited
MRZ-99030 – A novel modulator of Aβ aggregation: I – Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Neuropharmacology·2015· 31 cited
Effect of the Aβ Aggregation Modulator MRZ-99030 on Retinal Damage in an Animal Model of Glaucoma
Neurotoxicity Research·2014· 27 cited
The dopamine reuptake inhibitor MRZ-9547 increases progressive ratio responding in rats
The International Journal of Neuropsychopharmacology·2014· 76 citedOpen Access
Ocular and Systemic Distribution of the Developmental Glaucoma and Dry AMD drug MRZ-99030 in Pigmented Mouse, Rat, Rabbit, and Non-Human Primate
Investigative Ophthalmology & Visual Science·2014
MRZ-99030 - a novel modulator of β-amyloid (Aβ) aggregation for the topical neuroprotective treatment of glaucoma and age-related macular degeneration (AMD)
2014
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
BMC Ear Nose and Throat Disorders·2011· 62 citedOpen Access
Placebo influences on dyskinesia in Parkinson's disease
Movement Disorders·2008· 121 citedOpen Access
Dyskinesien bei Morbus Parkinson - Klinik, Ätiologie, Therapie
Fortschritte der Neurologie · Psychiatrie·2007· 1 cited
Prevalence and treatment strategies of dyskinesia in patients with Parkinson’s disease
Journal of Neural Transmission·2007· 17 cited
The Management Approaches to Dyskinesia Vary from Country to Country
Neuroepidemiology·2007· 7 cited
page 1 of 4Next →

Frequent Co-authors

H. Przuntek(13), E. Sch�mig(9), Edgar Schömig(7), Thomas Müller(6), Walter Mihatsch(5), Martin Gliese(4), Jörg Babin–Ebell(4), Dirk Woitalla(4), Christopher G. Goetz(3), Philippe Damier(3), C. Warren Olanow(3), Olivier Rascol(3), Fátima Martel(3), Doris-Anita Haeger(3), Chris G. Parsons(3), Bernd Friedgen(3), M. Gerlach(3), U. Trendelenburg(3), Yaniv Barkana(3), Christine Hicking(2)